Rosemarie Riddell Bogdan Graduates From Johns Hopkins Bloomberg School of Public Health and Is Appointed to Plaintiffs’ Science Subcommittee in National Depo-Provera Litigation
Albany, NY (May 2025) — Harding Mazzotti, LLP is pleased to announce that partner Rosemarie Riddell Bogdan has completed the Master of Public Health program at Johns Hopkins University. Rosemarie began the master’s program in 2023, seeking to formalize her knowledge in the field of public health, with a focus on epidemiology and pharmacoepidemiology. She earned her Master of Public Health degree and completed both the Epidemiology for Public Health Professionals and Pharmacoepidemiology and Drug Safety certificate programs along the way. About the program, Rosemarie said, “I have been so fortunate to have the opportunity to study under the guidance of the experts at the Johns Hopkins Bloomberg School. It was a wonderful journey, and I look forward to using my education to represent plaintiffs in medical device and pharmaceutical litigation.”
In the last session of her master’s studies, Rosemarie was appointed to a leadership position in the national Depo-Provera Liability Litigation (MDL No. 3140). Judge M. Casey Rodgers, who was assigned to preside over this important litigation by the U.S. Judicial Panel on Multidistrict Litigation, made the appointment by entering an order on March 16, 2025.
Rosemarie Riddell Bogdan has been appointed to the Plaintiffs’ Science and Expert Subcommittee, a fitting appointment given her credentials. This adds to the list of Attorney Bogdan’s national pharmaceutical and medical device litigation appointments. Prior to this, Attorney Bogdan was appointed to serve on the Plaintiffs’ Steering Committees in the Valsartan (MDL 2875), Zantac (MDL 2924), and Bard Hernia Mesh (MDL 3029) national product liability litigations.
Depo-Provera is an injectable contraceptive prescription medication administered every three months that has been associated with an increased risk of developing a type of brain tumor known as an intracranial meningioma. The litigation claims Pfizer misrepresented the long-term safety of the drug and failed to warn patients and healthcare providers of the increased risk of intracranial meningiomas. Recent studies have highlighted this increased risk. For example, one study found a 5.5 times higher risk of intracranial meningioma in women who used Depo-Provera for more than one year.
As a member of the Science Subcommittee, Bogdan will be analyzing the scientific evidence related to the relationship between taking Depo-Provera and meningiomas. This draws on Bogdan’s previous experience working as a Co-Science Chairperson and Science Committee Member in other medical device and pharmaceutical litigations.
“I am honored to be appointed by Judge Rodgers to this important litigation,” Bogdan said. “I look forward to my work on the Science Subcommittee on behalf of plaintiffs harmed by this drug.”
Attorney Bogdan has been dedicated to representing injured persons for over 30 years and is committed to representing those harmed by defective pharmaceuticals and medical devices. She represents individual plaintiffs in pharmaceutical and medical device litigations nationwide. If you or a loved one has used Depo-Provera and has been diagnosed with a meningioma, our Harding Mazzotti team, led by Attorney Bogdan, is here to answer your questions and discuss your legal options.
Harding Mazzotti, LLP® is a personal injury law firm whose practice is limited to protecting the rights of those wrongfully injured as a result of negligence. If you or a loved one have been injured, you can call our experienced team of attorneys toll-free at 1.800.LAW.1010 (1-800-529-1010).